Ra Capital Management, L.P. Sells 260,859 Shares of Vor Biopharma (NASDAQ:VOR) Stock

Vor Biopharma Inc. (NASDAQ:VOR) Director Ra Capital Management, L.P. sold 260,859 shares of the stock in a transaction on Friday, October 17th. The stock was sold at an average price of $29.39, for a total value of $7,666,646.01. Following the completion of the transaction, the director directly owned 15,104 shares of the company’s stock, valued at approximately $443,906.56. The trade was a 94.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Thursday, October 16th, Ra Capital Management, L.P. sold 151,803 shares of Vor Biopharma stock. The stock was sold at an average price of $29.45, for a total value of $4,470,598.35.
• On Wednesday, October 15th, Ra Capital Management, L.P. sold 51,363 shares of Vor Biopharma stock. The stock was sold at an average price of $30.55, for a total value of $1,569,139.65.

Vor Biopharma Stock Performance

NASDAQ:VOR opened at $29.00 on Friday. Vor Biopharma Inc. has a 1 year low of $2.62 and a 1 year high of $65.80. The company has a market capitalization of $198.77 million, a PE ratio of -0.11 and a beta of 2.07. The stock has a fifty day simple moving average of $36.55.

Vor Biopharma (NASDAQ:VOR) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($43.60) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Analyst Ratings Changes

Several analysts have recently weighed in on VOR shares. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Wedbush restated an “outperform” rating on shares of Vor Biopharma in a report on Thursday, June 26th. Wall Street Zen lowered Vor Biopharma to a “strong sell” rating in a report on Saturday, June 28th. Stifel Nicolaus raised Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a report on Wednesday, September 24th. Finally, Baird R W raised Vor Biopharma from a “hold” rating to a “strong-buy” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $77.83.

Institutional Investors Weigh In On Vor Biopharma

Several hedge funds have recently bought and sold shares of the business. Money Concepts Capital Corp lifted its stake in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company’s stock worth $37,000 after acquiring an additional 26,535 shares in the last quarter. XTX Topco Ltd purchased a new stake in Vor Biopharma in the 2nd quarter worth about $66,000. Goldman Sachs Group Inc. lifted its stake in Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company’s stock worth $61,000 after acquiring an additional 58,247 shares in the last quarter. OMERS ADMINISTRATION Corp purchased a new stake in Vor Biopharma in the 1st quarter worth about $100,000. Finally, Jane Street Group LLC purchased a new stake in Vor Biopharma in the 1st quarter worth about $140,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.